Stockscreener 앱 받기
34.01
1.25%
-0.43
시간 외 거래:
34.01
전일 마감가:
$34.44
열려 있는:
$34.59
하루 거래량:
742.66K
Relative Volume:
0.93
시가총액:
$3.91B
수익:
$22.50M
순이익/손실:
$-203.82M
주가수익비율:
-19.47
EPS:
-1.7469
순현금흐름:
$-148.03M
1주 성능:
+0.00%
1개월 성능:
+18.83%
6개월 성능:
-15.92%
1년 성능:
+111.77%
1일 변동 폭
$33.26
$34.75
1주일 범위
$33.26
$36.73
52주 변동 폭
$15.72
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
34.01 | 3.96B | 22.50M | -203.82M | -148.03M | -1.7469 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Resistance Check: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantQuarterly Trade Review & Real-Time Buy Zone Alerts - baoquankhu1.vn
NewAmsterdam Pharma Company (NAMS): Huge upside potential grabs attention of billionaire Stan Druckenmiller - MSN
Pullback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity Warrant2026 Fed Impact & Weekly Return Optimization Plans - baoquankhu1.vn
(NAMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-04-11 17:21:30 - baoquankhu1.vn
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Insider Monkey
Gains Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsEntry Point & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Does NewAmsterdam Pharma (NAMS) CETP Optimism Point To A Durable Edge In Cardiovascular Treatment? - Sahm
Short Squeeze: Will NewAmsterdam Pharma Company NV stock recover after earnings2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Billionaire Stan Druckenmiller’s 5 Small and Mid-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Discipline and Rules-Based Execution in NAMSW Response - Stock Traders Daily
Will NewAmsterdam Pharma Company NV benefit from seasonality2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
NAMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Two new hires get 15,000 stock options and 3,200 RSUs at NewAmsterdam - Stock Titan
Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 - Insider Monkey
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
Pullback Watch: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn
(NAMS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Revenue Check: Does NewAmsterdam Pharma Company NV have declining or rising EPSWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Will ACC.26 Obicetrapib Data on Kidney, Safety and Lipids Change NewAmsterdam Pharma's (NAMS) Narrative? - Sahm
Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) - Yahoo Finance
Behavioral Patterns of NAMSW and Institutional Flows - Stock Traders Daily
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
NewAmsterdam Pharma Announces Three Presentations at the - globenewswire.com
JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Earnings Update: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peersGap Up & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does NewAmsterdam Pharma Company NV have declining or rising EPSEarnings Beat & AI Forecasted Stock Moves - baoquankhu1.vn
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
(NAMS) Risk Channels and Responsive Allocation - Stock Traders Daily
Why is NewAmsterdam Pharma Company NV stock going downIPO Watch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Truist initiates NewAmsterdam Pharma stock coverage with buy rating By Investing.com - Investing.com India
Truist initiates NewAmsterdam Pharma stock coverage with buy rating - Investing.com
Published on: 2026-03-19 02:35:41 - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Fcpm Iii Services B.V. - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC's 5th Largest Position - MarketBeat
ArrowMark Colorado Holdings LLC Has $8.85 Million Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
(NAMSW) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Gains Report: Why is NewAmsterdam Pharma Company NV stock going down2026 Spike Watch & Daily Technical Stock Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $1,357,309.98 in Stock - MarketBeat
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NewAmsterdam Pharma Director Sells Shares - TradingView
Director at NewAmsterdam Pharma (NAMS) sells 44,619 shares - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):